Summary MMM released its Q1 2018 results on April 24, 2018 and revised its projected FY2018 GAAP EPS while leaving its adjusted projected EPS estimate unchanged. In my opinion, MMM was overvalued earlier in 2018 and the recent pullback has prompted me to increase my position. The company’s stock price could certainly pullback further but [...]
Summary In my January 31, 2018 article I stated that I perceived Stanley Black & Decker to be overvalued despite the pullback from its early January highs. Subsequent to my previous article, SWK has retraced further. SWK released its Q1 2018 results on April 20, 2018 and has revised its GAAP EPS range to $7.40 [...]
Summary On April 12, 2018, Genuine Parts (GPC) and Essendant (ESND) announced that the companies had entered into a definitive agreement to combine ESND and GPC’s S.P. Richards (SPR) business. On April 19, 2018, GPC reported Q1 results which reflected double digit sales growth but income before taxes experienced some challenges. Management has maintained its [...]
Summary Parker-Hannifin is a Dividend King having increased its annual dividend for at least 50 consecutive years. While the diluted - weighted-average common shares outstanding has been reduced dramatically since FY2008 and EPS has grown significantly since such time, there are other metrics that suggest PH is an unsuitable investment for me at this juncture. [...]
Summary Prestige Brands is a small cap company engaged in the business of marketing, sales, manufacturing and distribution of well-recognized, brand name, over-the-counter (“OTC”) healthcare and household cleaning products. It crossed my radar in December 2011 when it acquired 17 over-the-counter medicine brands sold in North America from GlaxoSmithKline Plc for $660 million cash. I [...]
Summary Altra is a small cap company which does not fit my investor profile. Some readers, however, have requested I conduct the occasional review on small cap investment opportunities hence this analysis. Altra released its Q4 and FY2017 results on February 21, 2018 and within days it announced a proposal to amalgamate with 4 operating [...]
Summary WST has been in business for 95 years and has developed a strong reputation. The top 50 injectable biologics rely on WST and also supplies the top 75 pharmaceutical and biotech injectable companies. The company’s common stock cumulative total return has far exceeded the cumulative total return of the following Standard & Poor's (“S&P”) [...]
Summary This RPM stock analysis is based on Q3 2018 results released on April 5, 2018. RPM increased its dividend in October 2017 thus marking its 44th consecutive year of dividend increases. The dividend compound annual growth rate for the 2001 – 2018, however, is only ~5.7%. RPM’s returns since May 31, 2007 have outperformed [...]
Summary Paychex reported strong Q3 results on March 26th and earlier in March it announced an acquisition in Germany which will offer PAYX the opportunity to expand its market penetration in Europe. The balance sheet is pristine and it continues to generate strong free cash flow. PAYX’s stock valuation has retraced from recent highs to [...]
Summary NKE reported Q3 results March 22, 2018 which were better than expected when the one-time ~$2B impact from the Tax Cuts and Job Act is excluded. Despite the tax hit, NKE has indicated the TCJ is slightly favorable in terms of its normalized steady state effective tax rate and because it will provide NKE [...]
